fda compounding semaglutide crackdown 2025 news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our US signals crackdown on compounded

Common side effects may include nausea, vomiting, diarrhea, and potential injection site reactions for Ozempic

I opted for the third generation Retatrutide, which now has a GLP-1, GIP, and glucagon receptor agonist (adding the glucagon agonist)

Cardiovascular Symptoms: Break Fast & Seek Emergency Help Signs: Chest pain or pressure Severe shortness of breath Irregular or very rapid heartbeat Numbness or weakness on one side of body Action: Break your fast immediately, call 999 - these are medical emergencies

[5] [6] For weight management, NICE technology appraisals (TA664 for semaglutide/Wegovy and TA662 for liraglutide/Saxenda) recommend use only within specialist weight management services for people meeting specific BMI thresholds with weight-related comorbidities

* P 0.05, ** P 0.01, *** P 0.001, and **** P 0.0001 by unpaired t test ( A C ), or 2-way ANOVA followed by Tukey post hoc tests ( D X )